Solubilization of free β-sitosterol in milk sphingomyelin and polar lipid vesicles as carriers: Structural characterization of the membranes and sphingosome morphology

Lopez, Christelle; David-Briand, Elisabeth; Lollier, Virginie; Mériadec, Cristelle; Bizien, Thomas; Pérez, Javier; Artzner, Franck

doi:10.1016/j.foodres.2023.112496

Cited by 3 publications

(2 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on their composition, lipoidal and non-lipoidal carriers are two types of vesicular drug delivery systems. Sphingosomes, 112–115 transferosomes, 116–122 liposomes, 123–129 emulsomes, 130–135 and virosomes are lipoidal carriers, 136–144 while aquasomes, 145–153 niosomes, 154–162 and bilosomes 163–178 are non-lipoidal. Nanoparticles, 179–185 polymeric micelles, 186–197 colloidal transfer systems 198–205 and other pharmacological carriers including biological macromolecules are suitable for targeted drug administration.…”

Section: Introductionmentioning

confidence: 99%

“…Based on their composition, lipoidal and non-lipoidal carriers are two types of vesicular drug delivery systems. Sphingosomes, [112][113][114][115] transferosomes, [116][117][118][119][120][121][122] liposomes, [123][124][125][126][127][128][129] emulsomes, [130][131][132][133][134][135] and virosomes are lipoidal carriers, [136][137][138][139][140][141][142][143][144] while aquasomes, [145][146][147][148][149][150][151][152][153] niosomes, [154][155][156][157][158][159][160]…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Review on novel targeted enzyme drug delivery systems: enzymosomes

Kumar,

Sachdeva,

Tanwar

et al. 2024

Soft Matter

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Review on novel targeted enzyme drug delivery systems: enzymosomes

Kumar,

Sachdeva,

Tanwar

et al. 2024

Soft Matter

View full text Add to dashboard Cite

show abstract

Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy

Yang

Zhou

et al. 2023

MedComm

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) have shown remarkable success in cancer treatment. However, in cancer patients without sufficient antitumor immunity, numerous data indicate that blocking the negative signals elicited by immune checkpoints is ineffective. Drugs that stimulate immune activation‐related pathways are emerging as another route for improving immunotherapy. In addition, the development of nanotechnology presents a promising platform for tissue and cell type‐specific delivery and improved uptake of immunomodulatory agents, ultimately leading to enhanced cancer immunotherapy and reduced side effects. In this review, we summarize and discuss the latest developments in nanoparticles (NPs) for cancer immuno‐oncology therapy with a focus on lipid‐based NPs (lipid‐NPs), including the characteristics and advantages of various types. Using the agonists targeting stimulation of the interferon genes (STING) transmembrane protein as an exemplar, we review the potential of various lipid‐NPs to augment STING agonist therapy. Furthermore, we present recent findings and underlying mechanisms on how STING pathway activation fosters antitumor immunity and regulates the tumor microenvironment and provide a summary of the distinct STING agonists in preclinical studies and clinical trials. Ultimately, we conduct a critical assessment of the obstacles and future directions in the utilization of lipid‐NPs to enhance cancer immunotherapy.

show abstract